Oxandrolone has been studied as an added treatment during specialist recovery from severe burns. Older trials reported gains in selected measures, including body mass and hospital stay.
On this page
Oxandrolone has been studied as an added treatment during specialist recovery from severe burns. Older trials reported gains in selected measures, including body mass and hospital stay. Later adult data were mixed. In the United States, the FDA withdrew Oxandrin approval in 2023. It cited an unfavorable balance of benefits and risks and inadequate evidence of effectiveness.[1]
Evidence boundary: burn research does not support self treatment, a personal amount, routine use after every burn or transfer of pediatric findings to adults. A study history does not create current approval.
Medical, legal and sport sources checked 2 September 2026. This material gives general information. It does not provide a diagnosis, prescription, amount, treatment calendar, product check or drug test timing.
What is oxandrolone?
Oxandrolone is a synthetic anabolic androgenic steroid. Archived United States labeling describes an oral tablet with molecular formula C19H30O3 and molecular mass 306.44 grams per mole. The label also records androgen activity, pituitary gonadotropin suppression and possible effects on sperm production.[3]
Oxandrin and Anavar are brand names associated with oxandrolone. A brand history does not prove that a current product is approved, authentic or suitable for a burn patient. The general identity and nonmedical interest in oxandrolone belong on the Anavar and oxandrolone page. This page stays with severe burn research and care limits.
| Active substance | Oxandrolone |
|---|---|
| Drug class | Synthetic anabolic androgenic steroid |
| Historical brand names | Oxandrin and Anavar |
| Recorded formula | C19H30O3 |
| Recorded molecular mass | 306.44 grams per mole |
| Archived United States route | Oral tablet |
| Current federal control | Schedule III in the United States |
| Current United States approval | Oxandrin approval and four generic applications were withdrawn in 2023 |
The old tablet label remains useful for chemical identity, warnings and historical wording. It is not proof that the product is currently approved in the United States.
Why can a severe burn cause prolonged muscle loss?
A large burn can trigger a sustained stress response. Resting energy use rises, inflammation persists and the body breaks down protein. Muscle loss can weaken breathing, movement and rehabilitation. Wound closure, graft care, infection control and nutrition place further demands on recovery.[9]
Oxandrolone was studied because androgen receptor activity can support protein synthesis and tissue growth. That mechanism explains the research question. It does not prove that every burn patient gains a net benefit. Age, burn size, organ function, infection, nutrition, surgery, rehabilitation and other medicines can change the result.
Research protocols placed the drug beside specialist burn care. They did not replace fluid care, surgery, wound management, nutrition, infection treatment, pain care or physical rehabilitation. A medicine effect cannot be separated from that background by reading the drug name alone.
What happened to Oxandrin approval in the United States?
Oxandrin was first approved in the United States in 1964. Its older label used broad language about weight gain after severe trauma and other causes of weight loss. That wording was not a current burn protocol and did not settle which burn patients should receive oxandrolone.
The FDA withdrew the Oxandrin application and four generic applications on 28 June 2023. In September 2023, the agency determined that Oxandrin had been withdrawn for reasons of safety or effectiveness. It cited serious liver and lipid warnings and a lack of substantial evidence of effectiveness.[2][1]
| Date | Authority record | Meaning for burn claims |
|---|---|---|
| 1964 | Initial Oxandrin approval | Historical approval began under older evidence and labeling standards. |
| 1984 | An FDA advisory committee found no evidence of effectiveness | The later FDA determination treated this as part of the evidence problem. |
| 2019 | The sponsor asked to withdraw the application because the product was no longer marketed | Commercial withdrawal alone did not answer the safety or effectiveness question. |
| 28 June 2023 | The FDA withdrew Oxandrin and four generic application approvals | The named approvals ended in the United States. |
| 13 September 2023 | The FDA found withdrawal for reasons of safety or effectiveness | The agency found an unfavorable balance without substantial evidence of effectiveness. |
| 31 October 2025 | The checked DailyMed record shows a marketing end date | An archived label can remain visible after marketing and approval status change. |
What have oxandrolone burn studies found?
The record includes rehabilitation studies, adult trials, pediatric trials and pooled reviews with different populations, care periods and outcomes.
| Record | Population and design | Reported finding | Main limit |
|---|---|---|---|
| 2003 rehabilitation study | People recovering from severe burns in a rehabilitation setting | Reported faster regain of body weight and lean mass than nutrition alone | Small, older study with a narrow recovery setting |
| 2006 adult trial | Randomized multicenter trial of 81 adults with burns over 20 to 60 percent of body surface area | Reported a shorter hospital stay for the studied group | The outcome does not prove lower mortality or benefit for smaller burns |
| 2012 pediatric trial | Single center trial in children with burns over 30 percent of body surface area and long follow up | Reported selected changes in growth, body composition, cardiac work and strength | Children received specialist care, and results cannot be transferred to adults or smaller burns |
| 2020 systematic review | Review of 31 burn studies | Reported selected gains in weight, lean mass, bone measures and some recovery outcomes | Studies varied in design, age, care stage and outcome definition |
| 2024 adult analysis | Post hoc study of 1,200 adults from an international trial dataset | Found mixed associations and a longer adjusted time to discharge among recipients | Clinicians chose oxandrolone, so illness severity and other confounding factors may explain part of the association |
| 2025 pooled review | Fourteen randomized trials with 2,822 patients | Reported selected recovery gains but no mortality or infection benefit | Very high variation across studies, and the pool included other androgen analogs and combined treatments |
The 2024 adult analysis is important because it does not repeat the simple benefit story. Oxandrolone use varied greatly between sites. Recipients often had larger burns or greater illness severity, and the drug itself was not randomly assigned. The authors described the adult findings as mixed and inconclusive.[8]
The 2025 review also needs careful reading. It pooled trials from 2005 through 2025 and reported selected recovery gains. It found no mortality benefit, no clear infection reduction and no donor site healing gain. Adult liver enzyme elevations were more common in the treatment groups. Variation across pooled studies was very high.[9]
What can the evidence support?
| Claim | Evidence level | Supported reading | Unsupported reading |
|---|---|---|---|
| Oxandrolone has been studied after severe burns | Established | Trials and reviews include adult and pediatric burn populations | It is appropriate after every burn |
| It can affect protein balance and body composition | Supported in selected settings | Some studies reported changes in lean mass, weight or metabolic measures | A predictable result for one patient |
| It shortens hospital stay | Conflicting | An older adult trial reported a shorter stay | A guaranteed shorter stay under current care |
| It improves survival | Not shown | Pooled research has not shown a mortality benefit | A life saving effect |
| It improves wound healing | Mixed | Some older reviews reported selected wound measures | Reliable donor site healing across populations |
| It is safe in severe burn care | Not established as a general claim | Some trials recorded limited adverse outcomes under specialist care | Safety for all ages, organs, medicines or treatment periods |
| It remains approved in the United States | False for the named applications | The FDA withdrew the named approvals in 2023 | An archived label proves current approval |
A group result may have uncertain value for one patient. Burn size, study age, background care, missing data and study design all matter.
Can pediatric findings be applied to adults?
No. Pediatric and adult evidence answers separate questions. Several influential pediatric studies came from one specialist center and enrolled children with very large burns under scheduled care.[6]
| Factor | Pediatric evidence | Adult evidence | Reason for caution |
|---|---|---|---|
| Growth | Height, bone maturation and puberty can be affected | Growth plate questions are different | The same outcome may have a different meaning by age |
| Burn burden | Many trials required burns over 30 percent of body surface area | Adult studies used other thresholds and case mixes | Findings do not represent a small outpatient burn |
| Background care | Specialist nutrition and rehabilitation were built into protocols | Care practices varied across sites | The drug cannot be separated from the care system by assumption |
| Organ and medicine context | Pediatric eligibility can exclude many adult conditions | Adults may have heart, liver, kidney or medicine interaction risks | Baseline risk changes the balance |
| Evidence design | Some randomized long follow up trials exist | The large 2024 adult study was observational for oxandrolone use | Random assignment and treatment selection answer different causal questions |
A burn team must assess the injury, current evidence, local approval status and the full clinical record.
What health risks matter with oxandrolone?
The archived label and the 2023 FDA finding describe serious concerns. These include peliosis hepatis, liver failure, internal abdominal bleeding, liver tumors, cholestatic hepatitis and adverse blood lipid changes. The FDA also cited hypercalcemia in some people with breast cancer and prostate concerns in older patients.[1][3]
| Area | Recorded concern | What a normal symptom check cannot rule out |
|---|---|---|
| Liver | Cholestatic hepatitis, jaundice, peliosis, tumors, liver failure or internal bleeding | Early liver injury can occur before severe pain or visible jaundice |
| Heart and blood vessels | Lower high density lipoprotein, higher low density lipoprotein, fluid retention and class wide cardiovascular concern | Blood pressure and lipid changes may be silent |
| Hormones and fertility | Suppressed gonadotropins, reduced natural testosterone and possible sperm suppression | Libido or energy cannot confirm fertility or endocrine recovery |
| Women and pregnancy | Voice change, facial hair, acne, menstrual change and fetal masculinization concern | Some virilizing changes may persist after exposure ends |
| Children | Accelerated bone maturation and disturbance of growth or sexual development | Height alone cannot show bone age or pubertal effects |
| Fluid and kidneys | Edema can complicate heart, kidney or steroid hormone problems | Ankle swelling or urine change needs context and may have several causes |
| Mental health and dependence | Broader anabolic steroid evidence includes mood change, dependence and withdrawal symptoms | A calm appearance does not rule out depression or dangerous thoughts |
Direct oxandrolone rates are unknown for many events. Burn illness can also alter liver tests, fluid balance, mood and blood values. Clinical interpretation must separate possible causes.[14][15]
Which interactions and higher risk settings need attention?
The archived label records a strong interaction with oral anticoagulants, including warfarin. Oxandrolone can increase anticoagulant sensitivity and bleeding risk. A patient using warfarin needs the prescribing team to know about every oxandrolone exposure. Medicine changes should not be made from an online summary.[3]
The label also records possible interactions with oral diabetes medicines. Corticosteroids or adrenocorticotropic hormone can add to edema. Pregnancy, nephrosis, hypercalcemia and certain breast or prostate cancers appear in the archived contraindication record.[3]
Burn care often involves pain medicines, antibiotics, anticoagulants, nutrition products and several clinical teams. A complete medicine list points because one interaction can affect bleeding, glucose, fluid balance, liver tests or rehabilitation. Product labels and photographs may help record a claim, but they do not confirm contents.
What may a specialist burn team assess?
A burn team first considers the injury, not one medicine. Relevant details include burn depth, total body surface area, airway injury, operations, grafts, infection, nutrition, mobility, pain, organ function and rehabilitation progress.
Medicine review may cover prescriptions, supplements, hormones, anticoagulants, diabetes medicines and unregulated products. Depending on the clinical question, assessment may include blood pressure, examination, blood count, liver and kidney measures, lipids, glucose, pregnancy status or hormone tests. No single panel answers every safety question.
Bring discharge records, medicine lists and product photographs. Report exposure dates and symptom changes. Honest disclosure can prevent a missed interaction or incorrect explanation.
Read how to talk with a doctor about anabolic steroid use and what blood tests can and cannot show.
What is the legal and sport status of oxandrolone?
Medicine approval, controlled drug law and sport rules answer different questions. The table gives current examples checked on 2 September 2026. Individual cases can depend on conduct, location, prescription facts and later rule changes.
| System | Record | Limit |
|---|---|---|
| United States federal law | Oxandrolone is listed as a Schedule III anabolic steroid.[10] | Federal scheduling does not describe every state rule or individual case. |
| United Kingdom | Oxandrolone appears as Class C and Schedule 4 Part 2.[11] | Possession, supply and import treatment differ under the applicable rules. |
| Canada | Oxandrolone appears in Schedule IV of the Controlled Drugs and Substances Act.[12] | The legal result depends on the conduct and any applicable authorization. |
| Competitive sport | The 2026 World Anti Doping Agency list prohibits oxandrolone under category S1 at all times.[13] | A research history or prior prescription does not by itself create a therapeutic use exemption. |
This is general information, not legal advice. The page does not provide a detection window, masking method or rule avoidance advice.
Can a label prove that a product contains oxandrolone?
No. A printed name, tablet color, seller statement or online photograph cannot prove identity, amount, purity or contamination status. An archived medicine label describes the named regulated product at a point in time. It does not authenticate material from another source.
A product sold as Anavar or oxandrolone may contain another active drug, an undeclared mixture or no oxandrolone. A chemical test answers only the method and sample examined. It cannot show that another tablet or batch is the same.
After a suspected exposure, retain packaging and write down the source claim, dates, symptoms and other medicines. Share the record with a clinician or poison service. Severe symptoms need emergency care rather than a product search.
References
- FDA determination that Oxandrin was withdrawn for reasons of safety or effectiveness. 2023.
- FDA withdrawal of Oxandrin and four oxandrolone applications. 2023.
- Archived United States oxandrolone tablet label. 2022.
- Oxandrolone and lean mass during rehabilitation after severe burns. 2003.
- Multicenter randomized trial in adults with severe burns. 2006.
- Five year pediatric oxandrolone trial after severe burns. 2012.
- Systematic review of oxandrolone in burn injuries. 2020.
- Adult burn analysis from the RE ENERGIZE trial dataset. 2024.
- Updated review of androgen analog trials in burn patients. 2025.
- Current United States Schedule III rule. 2026.
- United Kingdom controlled drugs list. 2025.
- Canada Controlled Drugs and Substances Act, Schedule IV. 2026.
- World Anti Doping Agency 2026 Prohibited List. 2026.
- Endocrine Society statement on health effects of performance drugs. 2014.
- Clinical review of anabolic androgenic steroid assessment. 2019.